Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB)

Alzheimer's and Dementia

Volumn 11, Issue 7, 2015, Pages 840-849

  Liu, Enchi ^a   Luthman, Johan ^b   Cedarbaum, Jesse M ^c   Schmidt, Mark E ^d   Cole, Patricia E ^e   Hendrix, James ^f   Carrillo, Maria C ^f   Jones Davis, Dorothy ^g   Tarver, Erika ^g   Novak, Gerald ^h   De Santi, Susan ⁱ   Soares, Holly D ^j   Potter, William Z ^k   Siemers, Eric ^l   Schwarz, Adam J ^l  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b EISAI INC   (United States)

^c BIOGEN   (United States)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e TAKEDA PHARMACEUTICALS   (United States)

^f ALZHEIMER'S ASSOCIATION   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁱ Piramal Enterprises Limited   (India)

^j Bristol Meyer Squibb   (United States)

^k NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^l ELI LILLY AND COMPANY   (United States)

more..

Author keywords

ADNI; Alzheimer's Disease Neuroimaging Initiative; FNIH; Foundation for the National Institutes of Health; Pharmaceutical industry; PPSB; Private Partner Scientific Board

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CLINICAL RESEARCH; COOPERATION; FUNCTIONAL NEUROIMAGING; HUMAN; NEUROIMAGING; PRIORITY JOURNAL; PROTEOMICS; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; BIOTECHNOLOGY; COGNITION DISORDERS; COMPLICATION; CONSULTATION; DRUG INDUSTRY; PROCEDURES; UNITED STATES;

ALZHEIMER DISEASE; BIOTECHNOLOGY; COGNITION DISORDERS; CONSULTANTS; DRUG INDUSTRY; HUMANS; NEUROIMAGING; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; UNITED STATES;

EID: 84937569445     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.04.001     Document Type: Review

References (28)

1. S.G. Mueller, M.W. Weiner, T.J. Thal, R.C. Petersen, C.R. Jack, W. Jagust, and et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimers Dement 1 2005 55 66
2. S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C. Jack, W. Jagust, and et al. The Alzheimer's Disease Neuroimaging Initiative Neuroimaging Clin N Am 15 2005 869 877 xi-xii
3. M.E. Schmidt, E. Siemers, P.J. Snyder, W.Z. Potter, P. Cole, and H. Soares The Alzheimer's Disease Neuroimaging Initiative: perspectives of the Industry Scientific Advisory Board Alzheimers Dement 6 2010 286 290
4. K. Marek, D. Jennings, S. Lasch, A. Siderowf, C. Tanner, T. Simuni, and et al. others. The Parkinson Progression Marker Initiative (PPMI) Prog Neurobiol 95 2011 629 635
5. H.M. Snyder, L.J. Bain, R. Egge, and M.C. Carrillo Alzheimer's disease public-private partnerships: a landscape of the global nonprofit community Alzheimers Dement 9 2013 466 471
6. H.D. Soares, W.Z. Potter, E. Pickering, M. Kuhn, F.W. Immermann, D.M. Shera, and et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease Arch Neurol 69 2012 1310 1317
7. D. Spellman, K.R. Wildsmith, L.A. Honigberg, M. Tuefferd, D. Baker, N. Raghavan, and et al. Development and evaluation of a multiplexed mass spectrometry-based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF Proteomics Clin Appl 2015 10.1002/prca.201400178 [Epub ahead of print].
8. M.J. Savage, D.J. Holder, G. Wu, J. Kaplow, J.A. Siuciak, W.Z. Potter the Foundation for the National Institutes of Health (FHIN) Biomarkers Consortium CSF Proteomics Project Team for the Alzheimer's Disease Neuroimaging Initiative Soluble BACE-1 activity and sAPPβ concentrations in AD and age-matched healthy control CSF from the Alzheimer's Disease Neuroimaging Initiative-1 baseline cohort J Alzheimers Dis 2015 http://dx.doi.org/10.3233/JAD-142778. [Epub ahead of print].
9. W.T. Hu, D.M. Holtzman, A.M. Fagan, L.M. Shaw, R. Perrin, S.E. Arnold, and et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease Neurology 79 2012 897 905
10. H. Soares, W. Potter, F. Immermann, E. Pickering, M. Kuhn, D. Shera, and et al. Changes in plasma based biomarkers in Alzheimer's disease, mild cognitively impaired and aged matched normal controls from the ADNI cohort Alzheimers Dement 7 2011 S329 S330
11. R. Craig-Shapiro, M. Kuhn, C. Xiong, E.H. Pickering, J. Liu, T.P. Misko, and et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis PLoS One 6 2011 e18850
12. J.T. Chiam, R.J. Dobson, S.J. Kiddle, and M. Sattlecker Are blood-based protein biomarkers for Alzheimer's disease also involved in other brain disorders? A systematic review J Alzheimers Dis 43 2015 303 314
13. N. Mattsson, U. Andreasson, S. Persson, H. Arai, S.D. Batish, S. Bernardini, and et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 7 2011 386 395.e6
14. N. Mattsson, I. Zeegers, U. Andreasson, M. Bjerke, M.A. Blankenstein, R. Bowser, and et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42 Biomark Med 6 2012 409 417
15. J. Waring, D. Slats, C. Gonzales, R. Dean, D. Lee, E. Siemers, and et al. An assessment of variability in CSF biomarkers in clinical experimental models: a meta-analysis Alzheimers Dement 7 2011 S101
16. H. Engler, A. Forsberg, O. Almkvist, G. Blomquist, E. Larsson, I. Savitcheva, and et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain 129 2006 2856 2866
17. W.J. Jagust, D. Bandy, K. Chen, N.L. Foster, S.M. Landau, C.A. Mathis, and et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core Alzheimers Dement 6 2010 221 229
18. J.O. Rinne, D.J. Brooks, M.N. Rossor, N.C. Fox, R. Bullock, W.E. Klunk, and et al. 11C-PiB PET assessment of change in fibrillar amyloid-ß load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol 9 2010 363 372
19. S. Ostrowitzki, D. Deptula, L. Thurfjell, F. Barkhof, B. Bohrmann, D.J. Brooks, and et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab Arch Neurol 69 2012 198 207
20. M.E. Schmidt, P. Chiao, G. Klein, D. Matthews, L. Thurfjell, P.E. Cole, and et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data Alzheimers Dement 2014 10.1016/j.jalz.2014.09.004 [Epub ahead of print]
21. R.A. Sperling, C.R. Jack Jr., S.E. Black, M.P. Frosch, S.M. Greenberg, B.T. Hyman, and et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Rountable Workgroup Alzheimers Dement 7 2011 367 385
22. L. Shen, P.M. Thompson, S.G. Potkin, L. Bertram, L.A. Farrer, T.M. Foroud, and et al. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers Brain Imaging Behav 8 2014 183 207
23. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, A.M. Fagan, and et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 280 292
24. J. Hobart, S. Cano, H. Posner, O. Selnes, Y. Stern, R. Thomas, and et al. Alzheimer's Disease Neuroimaging Initiative. Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods Alzheimers Dement 9 2013 S4 S9
25. J. Hobart, S. Cano, H. Posner, O. Selnes, Y. Stern, R. Thomas Alzheimer's Disease Neuroimaging Initiative Putting the Alzheimer's cognitive test to the test II: Rasch measurement theory Alzheimers Dement 9 2013 S10 S20
26. P.K. Crane, A. Carle, L.E. Gibbons, P. Insel, R.S. Mackin, A. Gross, and et al. Development and assessment of a composite score for memory in the ADNI Brain Imaging Behav 6 2012 502 516
27. J.L. Cummings, T. Morstorf, and K. Zhong Alzheimer's disease drug-development pipeline: few candidates, frequent failures Alzheimers Res Ther 6 2014 37
28. J.B. Toledo, N.J. Cairns, X. Da, K. Chen, D. Carter, A. Fleisher, and et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings Acta Neuropathol Commun 1 2013 65